Etcembly Ltd, a machine learning biotech that is assembling the world’s largest health and disease immune database, to revolutionise immunotherapy and personalised therapeutics, has moved into more than 1,000 sq ft of new laboratory and office premises within The Oxford Science Park (TOSP). The company, which recently closed an oversubscribed seed round with private investors, is now looking to hire talented scientists and data engineers to develop further its machine learning platform EMLy. The technology is expected to accelerate the discovery of novel immunotherapies for a range of diseases.
The founders and management team of Etcembly, Dr Michelle Teng, Chief Executive Officer, and Dr Jacob Hurst, Chief Technology Officer, have a unique blend of machine learning and immunology expertise. The company recently signed an exclusive research collaboration with Zelluna Immunotherapy.
Etcembly joins a group of thriving companies which use artificial intelligence techniques in their research. This includes Exscientia, using AI to precision engineer future drugs for patients and revolutionise drug discovery, MoA Technology, which is focused on the development of novel herbicides with positive environmental and economic impact and Sensyne Health which is applying clinical AI in health and life sciences.
Michelle Teng, CEO of Etcembly, said, ‘Our new laboratory and office facilities allow us to continue the company’s ambitious development plans following our recent fundraising and collaboration deal. We expect to thrive here in The Oxford Science Park’s environment of innovation and entrepreneurship.’
Rory Maw, Bursar of Magdalen College & Interim MD of TOSP, said, ‘We are delighted to see such an exciting company expanding here on the Park. Etcembly’s approach has great potential, and we expect it to have a major impact on health, alongside the other companies in the AI cohort at The Oxford Science Park.’